BioSpace News Archive

Photocure ASA reported Hexvix®/Cysview® revenues of NOK 115.9 million in the second quarter of 2023, and an EBITDA of NOK 23.4 million.

Anteris Technologies Ltd, reported that it has established a sponsored Level 1 American Depository Receipt program in the United States.

Mallinckrodt plc, a global specialty pharmaceutical company, reported results for the second quarter ended June 30, 2023.1

Form Bio , the breakthrough AI-powered drug discovery platform, announced today its notable achievements and product advancements for the first half of 2023.

Olink Holding AB announced its unaudited financial results for the second quarter ended June 30, 2023.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three months ended June 30, 2023.

Praxis Precision Medicines , Inc. today provided a corporate update and reported financial results for the second quarter 2023.

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and six months ended June 30, 2023.

Precigen, Inc. today announced that the US Food and Drug Administration (FDA) has agreed that the ongoing Phase 1/2 single arm study (NCT04724980) of the first-in-class investigational PRGN-2012 AdenoVerse™ immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP) will serve as pivotal for the purpose of filing an accelerated approval request for licensure.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”), today reported financial results for the second quarter of 2023.